Chen Li-Bo, Xu Jun-Yao, Yang Zhen, Wang Guo-Bin
Hepatobiliary center, Union Hospital of Huazhong University of Science and Technology, Wuhan 430022, Hubei province, China.
World J Gastroenterol. 2007 Nov 21;13(43):5718-24. doi: 10.3748/wjg.v13.i43.5718.
To investigate the role of SMYD3 in hepatocellular carcinoma (HCC) development and progression and to verify whether its regulation activity was through RIZ1 inactivation.
Expression of SMYD3 in HCC cell lines and tissues were measured; silencing of SMYD3 by RNA interference (RNAi) was effectuated, hepatoma cell proliferation, migration and apoptosis were tested, with RIZ1 CpG promoter methylation, and corresponding mRNA expression were investigated.
SMYD3 over-expression in HCC was associated with RIZ1 hypermethylation and mRNA down-expression. Suppression of SMYD3 expression de-methylated RIZ1 CpG promoter (P < 0.01) and increased RIZ1 mRNA expression (P < 0.01). Consequently, SMYD3 down-expression with RIZ1 de-methylation strongly inhibited hepatoma cell growth (MTT inhibitory rates: Pgenesil-1-s1 60.95% +/- 7.97%, Pgenesil-1-s2 72.14% +/- 9.68% vs Pgenesil-1-hk 6.89% +/- 4.12%, P < 0.01) and migration (Pgenesil-1-s1 4.24% +/- 1.58%, Pgenesil-1-s1 4.87% +/- 0.73% vs Pgenesil-1 19.03% +/- 4.63%, Pgenesil-1-hk 19.95% +/- 5.21%, P < 0.01) and induced apoptosis (FCM subG1 phase Pgenesil-1-s1 19.07% +/- 1.78%, Pgenesil-1-s2 17.68% +/- 2.36% vs Pgenesil-1 0.47% +/- 0.12%, Pgenesil-1-hk 1.46% +/- 0.28%, P < 0.01. TUNEL-positive cells: Pgenesil-1-s1 40.24% +/- 5.18%, Pgenesil-1-s2 38.48% +/- 4.65% vs Pgenesil-1 2.18% +/- 1.34%, Pgenesil-1-hk 2.84% +/- 1.22%, P < 0.01) in HepG2 cells.
These results demonstrate that SMYD3 plays a critical role in the carcinogenesis and progression of HCC. The proliferation, migration induction and apoptosis inhibition activities of SMYD3 may be mediated through RIZ1 CpG promoter hypermethylation.
研究SMYD3在肝细胞癌(HCC)发生发展中的作用,并验证其调控活性是否通过RIZ1失活实现。
检测HCC细胞系和组织中SMYD3的表达;通过RNA干扰(RNAi)使SMYD3沉默,检测肝癌细胞的增殖、迁移和凋亡情况,并研究RIZ1 CpG启动子甲基化及相应mRNA表达。
HCC中SMYD3的过表达与RIZ1高甲基化及mRNA低表达相关。抑制SMYD3表达可使RIZ1 CpG启动子去甲基化(P < 0.01)并增加RIZ1 mRNA表达(P < 0.01)。因此,SMYD3表达下调及RIZ1去甲基化可强烈抑制肝癌细胞生长(MTT抑制率:Pgenesil-1-s1为60.95%±7.97%,Pgenesil-1-s2为72.14%±9.68%,而Pgenesil-1-hk为6.89%±4.12%,P < 0.01)和迁移(Pgenesil-1-s1为4.24%±1.58%,Pgenesil-1-s1为4.87%±0.73%,而Pgenesil-1为19.03%±4.63%,Pgenesil-1-hk为19.95%±5.21%,P < 0.01),并诱导HepG2细胞凋亡(流式细胞术亚G1期:Pgenesil-1-s1为19.07%±1.78%,Pgenesil-1-s2为17.68%±2.36%,而Pgenesil-1为0.47%±0.12%,Pgenesil-1-hk为1.46%±0.28%,P < 0.01。TUNEL阳性细胞:Pgenesil-1-s1为40.24%±5.18%,Pgenesil-1-s2为38.48%±4.65%,而Pgenesil-1为2.18%±1.34%,Pgenesil-1-hk为2.84%±1.22%,P < 0.01)。
这些结果表明SMYD3在HCC的致癌作用和进展中起关键作用。SMYD3的增殖、迁移诱导和凋亡抑制活性可能通过RIZ1 CpG启动子高甲基化介导。